SNDX · NASDAQ
Syndax Pharmaceuticals, Inc.
$13.30 -0.10 (-0.75%)
Company overview
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in Phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML), and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has a collaborative research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.2B
- Employees
- 270
- Headquarters
- New York City, MA
- Website
- syndax.com
- CEO
- Michael A. Metzger
- Listed
- March 2, 2016
- P/E
- -4.75
- Dividend yield
- 0.00%
Company financials
- Revenue
- $217M
- Gross profit
- $213M
- Operating income
- -$224M
- EBITDA
- -$163M
- Net income
- -$243M
- EPS
- -$2.80
- Total assets
- $473M
- Total debt
- $345M
- Gross margin
- 97.96%
- Net margin
- -112.01%
- Earnings yield
- -21.05%
No geographic segmentation.
Showing FY 2025
SNDX
1D
NASDAQ
O13.60H13.61L13.20C13.40-0.17 (-1.25%)Vol4.25M